872355-60-7

Basic information

• Product Name: METHYL 5-AMINO-6-IODOPICOLINATE
• Synonyms: METHYL 5-AMINO-6-IODOPICOLINATE;methyl 5-amino-6-iodopyridine-2-carboxylate;5-Amino-6-iodo-pyridine-2-carboxylic acid methyl ester;methyl5-amino-6-iodopicolinate(WX191808)
• CAS NO: 872355-60-7
• Molecular Formula: C₇H₇IN₂O₂
• Molecular Weight: 278.04715
• Mol File: 872355-60-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL 5-AMINO-6-IODOPICOLINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-AMINO-6-IODOPICOLINATE(872355-60-7)
• EPA Substance Registry System: METHYL 5-AMINO-6-IODOPICOLINATE(872355-60-7)

Safety Data

• Hazardous Substances Data: 872355-60-7(Hazardous Substances Data)

Upstream product

• 67515-76-8 methyl 5-amino-2-pyridinecarboxylate 
• 55338-73-3 5-amino-2-cyanopyridine 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 

Downstream Products

• 872355-64-1 1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid 
• 872355-63-0 methyl 1H-pyrrolo[3,2-b]pyridine-5-carboxylate 

Relevant articles and documents

TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a triazine derivative having EGFR inhibitory activity, a preparation method therefor and use thereof. In particular, disclosed are an EGFR inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, use thereof for preparing the EGFR inhibitor, and use thereof in preparing medicaments for treating and/or preventing cancers, tumors or metastatic diseases at least partially related to insertion, deletion or other mutation of EGFR exon 20, and in particular use thereof in preparing medicaments for treating and/or preventing hyperproliferative diseases and diseases inducing cell death disorders. The definition of each substituent of formula (I) is the same as that in the description.

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.